drugset
drugset / Trial / NCT03523819

A Study of CS1002 in Subjects with Advanced Solid Tumors

NCT03523819 ↗

Phase 1 Completed 91 enrolled CStone Pharmaceuticals
RandomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.

Timeline

Start
2018-04-26
Primary completion
2022-01-18
Completion
2022-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject CS1002 Monoclonal antibody — Intravenous
Subject CS1003 Monoclonal antibody 200 mg Intravenous

Indications

cancer